A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Bevacizumab (NSC #704865 IND #7921) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of the study is to compare treatment with gemcitabine plus docetaxel to treatment with gemcitabine plus docetaxel plus the addition of a third drug, called bevacizumab.
Description
The purpose of the study is to compare treatment with gemcitabine plus docetaxel to treatment with gemcitabine plus docetaxel plus the addition of a third drug, called bevacizumab.
Details
| Condition | Leiomyosarcoma of the Uterus |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX1502 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.